Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 12022708

Tamsulosin: an overview.

Christopher Chapple·Karl-Erik Andersson
View original source ↗Export metadata ↓

Abstract

This article reviews the contemporary literature related to tamsulosin, which is now the most widely used alpha antagonist in treating benign prostatic hyperplasia. The primary emphasis of this article is on the clinical data that exist related to this agent. Currently, there are no adequate studies that effectively compare existing agents for the treatment of benign prostatic hyperplasia using a randomised, placebo-controlled design with adequate numbers and this needs to be addressed in future studies.

Explore related subjects

Adrenergic alpha-AntagonistsAgedDose-Response Relationship, DrugDrug Administration ScheduleEuropeFollow-Up StudiesHumansJapanMaleMiddle AgedProstatic HyperplasiaRandomized Controlled Trials as TopicSulfonamidesTamsulosinTreatment OutcomeUnited StatesComparative StudyJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Christopher Chapple, Karl-Erik Andersson. 2002. Tamsulosin: an overview.. https://doi.org/10.1007/s00345-002-0246-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

An endocrinological update in toads: disparity between the cardiovascular effects of two angiotensin II analogs.

This study was undertaken to test the hypothesis that, in toads, the pressor effects of angiotensin II (ANG II) are partly due to the secondary effects of catecholamines. In Bufo marinus, blood pressure responses to bullfrog ([Val(5)]) ANG II administration were measured in animals pretreated (experimental group) and not pretreated (control group) with phentolamine, an alpha-adrenergic antagonist. At 1, 2, and 4 min following ANG II administration (50 ngkg(-1)), mean arterial pressure (MAP) of the experimental group was significantly less than in the control group (27.9+/-1.0, 28.2+/-1.6, and 25.8+/-2.1 mmHg versus 45.1+/-1.0, 39.4+/-2.8, and 35.5+/-3.6, respectively; n=6). Heart rate (f(H)) was unaffected by phentolamine. These data support our hypothesis. Previous authors, using human ([Ile(5)]) ANG II, have concluded that alpha-adrenergic mechanisms are not involved in the pressor effects of ANG II in B. marinus. In a separate group of toads, we examined MAP and f(H) responses to similar doses of human and bullfrog ANG II (100 ngkg(-1)). Bullfrog ANG II caused MAP to reach higher peak values (56.5+/-2.6 versus 37.2+/-0.4 mmHg; n=7) in less time (approximately 1 min versus approximately 8 min) than human ANG II. Furthermore, bullfrog ANG II caused f(H) to significantly increase from 41.3+/-5.1 to 79.3+/-2.3 beats min(-1) (at 1 min) whereas human ANG II caused no significant changes in f(H) throughout the measured time course. Higher doses of human ANG II (100 microgkg(-1)) invoked slow but large increases in MAP with non-significant decreases in f(H). These additional data suggest that the choice of exogenously administered hormone is an important one to consider in comparative endocrinological studies.

Adrenergic alpha-Antagonists↗
PubMed2003

Selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in human plasma.

A selective, sensitive and rapid liquid chromatography-tandem mass spectrometry method for the determination of alfuzosin in plasma was developed. A PE Sciex API 2,000 triple quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode, using TurboIonSpray with positive ionisation was used. Using prazosin as an internal standard, liquid-liquid extraction was followed by C(18) reversed-phase liquid chromatography and tandem mass spectrometry. The mean recovery for alfuzosin was 82.9% with a lower limit of quantification set at 0.298 ng/ml, the calibration range being between 0.298 and 38.1 ng/ml. This assay method makes use of the increased sensitivity and selectivity of tandem mass spectrometric (MS-MS) detection to allow for a more rapid (extraction and chromatography) and selective method for the determination of alfuzosin in human plasma than has previously been described. The assay method was used to quantify alfuzosin in human plasma samples generated in a multiple-dose (5 mg bd.) study at steady state.

Adrenergic alpha-Antagonists↗
PubMed2003

Chronic cold stress sensitizes brain noradrenergic reactivity and noradrenergic facilitation of the HPA stress response in Wistar Kyoto rats.

Many psychiatric disorders, including depression, post-traumatic stress disorder and other anxiety disorders, result from an interaction between genetic factors and exposure to a sufficiently sensitizing environmental stressor. The inbred Wistar Kyoto (WKY) rat strain has been proposed as a model of stress vulnerability, exhibiting an exaggerated hypothalamic-pituitary-adrenal (HPA) response to stress and susceptibility to gastric ulceration. Previously, we showed that stress-activation of the brain noradrenergic system was deficient in WKY rats, and they lacked noradrenergic facilitation of the HPA response in the lateral bed nucleus of the stria terminalis (BSTL), compared to outbred Sprague-Dawley (SD) controls. Deficient modulatory function of the noradrenergic system may contribute to the stress susceptibility of WKY rats. Thus, we investigated the influence of a sensitizing stimulus, chronic intermittent cold exposure, on neuroendocrine and noradrenergic stress reactivity, and on noradrenergic facilitation of the HPA response in these two strains. Chronic cold exposure (7 days, 4 h/day, 4 degrees C) potentiated activation of the HPA axis by acute immobilization stress, assessed by measuring plasma adrenocorticotropic hormone (ACTH), in both strains, although to a greater extent in WKY rats, and enhanced stress-induced norepinephrine (NE) release in BSTL of WKY but not SD rats. We then compared the influence of chronic cold exposure on noradrenergic modulation of the HPA stress response in BSTL, by measuring changes in acute stress-induced elevation of plasma ACTH after microinjecting the alpha(1)-adrenoreceptor antagonist benoxathian into the BSTL. As shown previously, benoxathian attenuated stress-induced ACTH secretion in control SD but not control WKY rats. After chronic cold, the ACTH response to acute stress was attenuated by benoxathian administration into BSTL of both strains, such that the WKY response was not different from that of SD rats. Thus, chronic cold not only sensitized the release of NE in BSTL of WKY rats, but also restored noradrenergic facilitation of their already-elevated HPA response. Such functional sensitization of a previously-deficient facilitatory system may be one mechanism whereby exposure to repeated or severe stress may induce pathologic dysregulation of the stress response in susceptible individuals, resulting in psychiatric illness.

Adrenergic alpha-Antagonists↗